Cathie's Ark LogoCathie's Ark
Trading Floor Community IconFrom the Trading Floor:
Seres Therapeutics Inc Logo

ARKK Holdings of Seres Therapeutics (MCRB) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
September 7, 2021SELL260ARKK
September 3, 2021SELL11856ARKK
September 2, 2021SELL50000ARKK
September 1, 2021SELL519570.0015%ARKK
August 31, 2021SELL5767620.0162%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$5.46
⚖️Weighting🧢Market Cap
0%$500.78m
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
4916.71
🏋️‍♀️Weight Rank Across All Funds🌏Country
281🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$8.200%
Description
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
Website
www.serestherapeutics.com

Research Notes and Commentary for MCRB

No Research Notes Found for MCRB